We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

15 hedge funds and large institutions have $2.94M invested in Evoke Pharma in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

387% more capital invested

Capital invested by funds: $604K → $2.94M (+$2.33M)

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

50% more funds holding

Funds holding: 10 → 15 (+5)

22.36% more ownership

Funds ownership: 15.54% → 37.9% (+22%)

Holders
15
Holders Change
+5
Holders Change %
+50%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
4
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$790K
2
NWMG
National Wealth Management Group
Ohio
+$398K
3
BL
Bleichroeder LP
New York
+$385K
4
DS
DRW Securities
Illinois
+$118K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$93.1K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$33K
2
TRCT
Tower Research Capital (TRC)
New York
-$9.66K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$792
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$792K +$790K +159,294 +248,897%
NCM
2
Nantahala Capital Management
Connecticut
$736K – – –
BL
3
Bleichroeder LP
New York
$728K +$385K +77,645 +113%
NWMG
4
National Wealth Management Group
Ohio
$398K +$398K +80,130 New
DS
5
DRW Securities
Illinois
$118K +$118K +23,742 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$93.2K +$93.1K +18,759 New
TSS
7
Two Sigma Securities
New York
$51.9K +$51.8K +10,437 New
Osaic Holdings
8
Osaic Holdings
Arizona
$16.4K +$14.9K +3,010 New
Northwestern Mutual Wealth Management
9
Northwestern Mutual Wealth Management
Wisconsin
$1.35K +$1.35K +272 New
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$1K +$943 +190 New
BlackRock
11
BlackRock
New York
$606 – – –
SS
12
SBI Securities
Japan
$378 +$5 +1 +1%
TRCT
13
Tower Research Capital (TRC)
New York
$199 -$9.66K -1,948 -98%
NA
14
NewEdge Advisors
Louisiana
$84 – – –
Bank of America
15
Bank of America
North Carolina
$60 +$10 +2 +20%
Citadel Advisors
16
Citadel Advisors
Florida
– -$33K -12,542 Closed
Fidelity Investments
17
Fidelity Investments
Massachusetts
– -$792 -301 Closed

EVOK Hedge Fund Activity: Q3 2025 in Review

15 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2025, worth a combined $2.94M — up 387% from $604K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new EVOK positions and 2 closed out — a net gain of 5 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $790K. The largest seller was Citadel Advisors, exiting entirely with an estimated $33K sold.

  • 15 institutional investors held Evoke Pharma (EVOK) as of Q3 2025, up from 10 in Q2 2025.
  • Funds reported $2.94M of Evoke Pharma stock for Q3 2025, up 387% quarter-over-quarter.
  • 7 funds opened new Evoke Pharma positions in Q3 2025 and 2 closed out, a net change of +5 holders.
  • The largest Evoke Pharma buyer in Q3 2025 was Morgan Stanley, an estimated $790K added.
  • The largest Evoke Pharma seller in Q3 2025 was Citadel Advisors, an estimated $33K sold.

Based on aggregated 13F filings for Q3 2025.